The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial.
The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial.
BackgroundFor adults surviving stroke due to spontaneous (non-traumatic) intracerebral haemorrhage (ICH) who had taken an antithrombotic (i.e. anticoagulant or antiplatelet) drug for the prevention of vaso-occlusive disease before the ICH, it is unclear whether starting antiplatelet drugs results in an increase in the risk of recurrent ICH or a beneficial net reduction of all serious vascular events compared to avoiding antiplatelet drugs.Methods/designThe REstart or STop Antithrombotics Randomised Trial (RESTART) is an investigator-led, randomised, open, assessor-blind, parallel-group, randomised trial comparing starting versus avoiding antiplatelet drugs for adults surviving antithrombotic-associated ICH at 122 hospital sites in the United Kingdom. RESTART uses a central, web-based randomisation system using a minimisation algorithm, with 1:1 treatment allocation to which central research staff are masked. Central follow-up includes annual postal or telephone questionnaires to participants and their general (family) practitioners, with local provision of information about adverse events and outcome events. The primary outcome is recurrent symptomatic ICH. The secondary outcomes are: symptomatic haemorrhagic events; symptomatic vaso-occlusive events; symptomatic stroke of uncertain type; other fatal events; modified Rankin Scale score; adherence to antiplatelet drug(s). The magnetic resonance imaging (MRI) sub-study involves the conduct of brain MRI according to a standardised imaging protocol before randomisation to investigate heterogeneity of treatment effect according to the presence of brain microbleeds. Recruitment began on 22 May 2013. The target sample size is at least 720 participants in the main trial (at least 550 in the MRI sub-study).DiscussionFinal results of RESTART will be analysed and disseminated in 2019.Trial registrationISRCTN71907627 ( www.isrctn.com/ISRCTN71907627 ). Prospectively registered on 25 April 2013.
Al-Shahi, Salman R
04a9ae6b-1d96-4c4e-a9b7-b996a756641e
Innes, K
4423c9f2-75f4-4265-b550-aaec6f490c26
Drever, J
67cfa56d-b95e-4fe2-9352-e3c9febc81c1
Dinsmore, L
b1774b81-128d-49a3-9e8c-e1e6004a7050
Williams, C
2f3c5203-6fbe-432d-a2ad-f039983069e4
Sprigg, N
e3b7cfda-3b49-4c8f-b5cb-b13a77debaf9
5 March 2018
Al-Shahi, Salman R
04a9ae6b-1d96-4c4e-a9b7-b996a756641e
Innes, K
4423c9f2-75f4-4265-b550-aaec6f490c26
Drever, J
67cfa56d-b95e-4fe2-9352-e3c9febc81c1
Dinsmore, L
b1774b81-128d-49a3-9e8c-e1e6004a7050
Williams, C
2f3c5203-6fbe-432d-a2ad-f039983069e4
Sprigg, N
e3b7cfda-3b49-4c8f-b5cb-b13a77debaf9
Al-Shahi, Salman R, Innes, K, Drever, J, Dinsmore, L, Williams, C and Sprigg, N
(2018)
The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial.
Trials, 19 (162).
(doi:10.1186/s13063-018-2542-6).
Abstract
BackgroundFor adults surviving stroke due to spontaneous (non-traumatic) intracerebral haemorrhage (ICH) who had taken an antithrombotic (i.e. anticoagulant or antiplatelet) drug for the prevention of vaso-occlusive disease before the ICH, it is unclear whether starting antiplatelet drugs results in an increase in the risk of recurrent ICH or a beneficial net reduction of all serious vascular events compared to avoiding antiplatelet drugs.Methods/designThe REstart or STop Antithrombotics Randomised Trial (RESTART) is an investigator-led, randomised, open, assessor-blind, parallel-group, randomised trial comparing starting versus avoiding antiplatelet drugs for adults surviving antithrombotic-associated ICH at 122 hospital sites in the United Kingdom. RESTART uses a central, web-based randomisation system using a minimisation algorithm, with 1:1 treatment allocation to which central research staff are masked. Central follow-up includes annual postal or telephone questionnaires to participants and their general (family) practitioners, with local provision of information about adverse events and outcome events. The primary outcome is recurrent symptomatic ICH. The secondary outcomes are: symptomatic haemorrhagic events; symptomatic vaso-occlusive events; symptomatic stroke of uncertain type; other fatal events; modified Rankin Scale score; adherence to antiplatelet drug(s). The magnetic resonance imaging (MRI) sub-study involves the conduct of brain MRI according to a standardised imaging protocol before randomisation to investigate heterogeneity of treatment effect according to the presence of brain microbleeds. Recruitment began on 22 May 2013. The target sample size is at least 720 participants in the main trial (at least 550 in the MRI sub-study).DiscussionFinal results of RESTART will be analysed and disseminated in 2019.Trial registrationISRCTN71907627 ( www.isrctn.com/ISRCTN71907627 ). Prospectively registered on 25 April 2013.
Text
s13063-018-2542-6
- Version of Record
More information
Accepted/In Press date: 12 February 2018
Published date: 5 March 2018
Identifiers
Local EPrints ID: 506034
URI: http://eprints.soton.ac.uk/id/eprint/506034
ISSN: 1745-6215
PURE UUID: 53ff5acb-3c46-48da-a1ac-524c15cf8f30
Catalogue record
Date deposited: 28 Oct 2025 17:32
Last modified: 28 Oct 2025 17:41
Export record
Altmetrics
Contributors
Author:
Salman R Al-Shahi
Author:
K Innes
Author:
J Drever
Author:
L Dinsmore
Author:
C Williams
Author:
N Sprigg
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics